恶性肿瘤患者凝血指标检测的临床价值  

Clinical Value of Blood Coagulating Index Detection in Patients with Malignant Tumor

作　　者：余佩芝[1] 秦建川[1] 郑志龙[1] 

机构地区：[1]广东药学院附属第一医院检验科,广州510080

出　　处：《血栓与止血学》2016年第2期165-167,170,共4页Chinese Journal of Thrombosis and Hemostasis

摘　　要：目的探讨恶性肿瘤患者凝血指标的检测在肿瘤诊治过程中的价值。方法对268例恶性肿瘤患者和50例健康对照者的凝血指标凝血酶原时间(PT)、部分凝血活酶时间(a PTT)、纤维蛋白原(Fbg)、凝血酶时间(TT)、D二聚体(D-D)的检测结果进行比较和分析。结果 85.1%的恶性肿瘤患者有一项以上的凝血指标异常,其中D-D异常率最高,Fbg次之。PT、a PTT、Fbg、D-D的测定值与对照组比较差异有统计学意义。而TT则无统计学上的差异。结论对恶性肿瘤患者的凝血指标尤其是D-D和Fbg进行监测,有助于观察肿瘤患者的高凝状态,减少并发症的发生。Objective To investigate the clinical value of blood coagulating indices in patients with malignant tumor. Methods The measured results of PT、a PTT、Fbg、TT、D-D,were compared and statistically analyzed in 268 patients with malignant tumor and fifty healthy controls. Results Trere are more than a blood coagulating idnex are abnormal in 85. 1% of the patients with maligmant tumor. Including the highest rate of abnormal in D-D,and the second is Fbg. Compared with healthy control group,the measured results of blood coagulating indexes（ PT、a PTT、Fbg、D-D） were statistical defferences,but there was no significant difference in the TT. Conclusion Monitoring of blood coagulating indexes especially D-D and Fbg in patients with malignant tumor,helps to observe the patients with high coagulating state,reduce the occurrence of complication.

关 键 词：恶性肿瘤 凝血功能 D二聚体 纤维蛋白原 

分 类 号：R730.43[医药卫生—肿瘤]